FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210173192> ?p ?o ?g. }

• W3210173192 endingPage "S460" @default.
• W3210173192 startingPage "S460" @default.
• W3210173192 abstract "Introduction: Previous studies have demonstrated that exposure to anti-TNFα medications or immunomodulators (IMM) does not increase the risk of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a previous history of cancer. There is little data regarding this risk after the use of newer biologics such as ustekinumab and vedolizumab. In this study, we assessed whether patients with IBD and a history of previous cancer who are exposed to these newer agents have an increased risk of developing subsequent cancer. Methods: We performed a retrospective cohort study of patients with IBD and cancer from a single academic medical center between January 2013 and December 2020. We recorded information on demographics, cancer type and treatment, and IBD characteristics and drug exposures. The primary exposure was type of IBD monotherapy after a cancer diagnosis. The primary outcome was development of new or recurrent cancer. Results: Of 401 patients with IBD and a history of cancer, 37 subsequently received vedolizumab, 14 ustekinumab, 31 IMM, 41 anti-TNF, 11 combination anti-TNF with an IMM, and 267 were not exposed to any immunosuppression following a cancer diagnosis (Table 1). There were no differences in duration of IBD, median age at cancer diagnosis, or smoking history. During a total median follow-up of 52 months, 81 (20%) patients developed incident cancer including 6 (16%) exposed to vedolizumab, 2 (14%) to ustekinumab, 3 (10%) to IMM, 12 (29%) to anti-TNF, 2 (18%) to combination anti-TNF with an IMM, and 56 (21%) with no immunosuppression (P = 0.41). Sensitivity analyses assessing any history of exposure to vedolizumab or ustekinumab, inclusive of both single and multiple biologic exposures, also did not reveal an increased rate of incident cancer. Conclusion: In this single-center study, vedolizumab or ustekinumab monotherapy in patients with IBD and a history of cancer was not associated with an increase in new or recurrent cancer compared with anti-TNF, IMM, or no immunosuppression. Prospective studies are needed to confirm this conclusion.Table 1.: Proportions reported as no. (%). Continuous variables reported as mean ± SD. *6-mercaptopurine, azathioprine ** infliximab, adalimumab or golimumabFigure 1.: At 5 years, there was no significant difference in cancer-free survival between groups (P = 0.76)." @default.
• W3210173192 created "2021-11-08" @default.
• W3210173192 creator A5009295279 @default.
• W3210173192 creator A5012629328 @default.
• W3210173192 creator A5016785345 @default.
• W3210173192 creator A5023694681 @default.
• W3210173192 creator A5037576846 @default.
• W3210173192 creator A5039145221 @default.
• W3210173192 creator A5072158096 @default.
• W3210173192 creator A5081605770 @default.
• W3210173192 date "2021-10-01" @default.
• W3210173192 modified "2023-09-27" @default.
• W3210173192 title "S961 Risk of New or Recurrent Cancer After Vedolizumab or Ustekinumab Exposure in Patients With Inflammatory Bowel Disease and Previous Cancer" @default.
• W3210173192 doi "https://doi.org/10.14309/01.ajg.0000777376.85467.82" @default.
• W3210173192 hasPublicationYear "2021" @default.
• W3210173192 type Work @default.
• W3210173192 sameAs 3210173192 @default.
• W3210173192 citedByCount "0" @default.
• W3210173192 crossrefType "journal-article" @default.
• W3210173192 hasAuthorship W3210173192A5009295279 @default.
• W3210173192 hasAuthorship W3210173192A5012629328 @default.
• W3210173192 hasAuthorship W3210173192A5016785345 @default.
• W3210173192 hasAuthorship W3210173192A5023694681 @default.
• W3210173192 hasAuthorship W3210173192A5037576846 @default.
• W3210173192 hasAuthorship W3210173192A5039145221 @default.
• W3210173192 hasAuthorship W3210173192A5072158096 @default.
• W3210173192 hasAuthorship W3210173192A5081605770 @default.
• W3210173192 hasBestOaLocation W32101731921 @default.
• W3210173192 hasConcept C121608353 @default.
• W3210173192 hasConcept C126322002 @default.
• W3210173192 hasConcept C143998085 @default.
• W3210173192 hasConcept C2776207728 @default.
• W3210173192 hasConcept C2777138892 @default.
• W3210173192 hasConcept C2778260677 @default.
• W3210173192 hasConcept C2778975655 @default.
• W3210173192 hasConcept C2779134260 @default.
• W3210173192 hasConcept C2779280984 @default.
• W3210173192 hasConcept C526805850 @default.
• W3210173192 hasConcept C71924100 @default.
• W3210173192 hasConceptScore W3210173192C121608353 @default.
• W3210173192 hasConceptScore W3210173192C126322002 @default.
• W3210173192 hasConceptScore W3210173192C143998085 @default.
• W3210173192 hasConceptScore W3210173192C2776207728 @default.
• W3210173192 hasConceptScore W3210173192C2777138892 @default.
• W3210173192 hasConceptScore W3210173192C2778260677 @default.
• W3210173192 hasConceptScore W3210173192C2778975655 @default.
• W3210173192 hasConceptScore W3210173192C2779134260 @default.
• W3210173192 hasConceptScore W3210173192C2779280984 @default.
• W3210173192 hasConceptScore W3210173192C526805850 @default.
• W3210173192 hasConceptScore W3210173192C71924100 @default.
• W3210173192 hasIssue "1" @default.
• W3210173192 hasLocation W32101731921 @default.
• W3210173192 hasLocation W32101731922 @default.
• W3210173192 hasOpenAccess W3210173192 @default.
• W3210173192 hasPrimaryLocation W32101731921 @default.
• W3210173192 hasRelatedWork W2317479536 @default.
• W3210173192 hasRelatedWork W2586347006 @default.
• W3210173192 hasRelatedWork W2767911405 @default.
• W3210173192 hasRelatedWork W3021087471 @default.
• W3210173192 hasRelatedWork W3048212227 @default.
• W3210173192 hasRelatedWork W3092454324 @default.
• W3210173192 hasRelatedWork W3135634162 @default.
• W3210173192 hasRelatedWork W3162431080 @default.
• W3210173192 hasRelatedWork W4310184611 @default.
• W3210173192 hasRelatedWork W4367556927 @default.
• W3210173192 hasVolume "116" @default.
• W3210173192 isParatext "false" @default.
• W3210173192 isRetracted "false" @default.
• W3210173192 magId "3210173192" @default.
• W3210173192 workType "article" @default.